inv (4)(p13q13) in patient with essential thrombocythemia: A case report  by Aydin, Cigdem et al.
case reportinv (4)(p13q13) in patient with
essential thrombocythemia: A case
reportHematol Oncol Stem Cell Ther 8(4) Fourth Quarter 2015Cigdem Aydin a, Ozan Salim b, Orhan Kemal Yucel b, Levent Undar b, Sibel Berker Karauzum c,*
a Mehmet Akif Ersoy University, Bucak School of Health, Department of Nursing, Burdur, Turkey, b Akdeniz University, Faculty of
Medicine, Department of Hematology, Antalya, Turkey, c Akdeniz University, Faculty of Medicine, Department of Medical Biology and
Genetics, Antalya, Turkey
* Corresponding author. Tel.: +90 242 249 69 70. Æ sibelberker@akdeniz.edu.tr Æ Received for publication 16 October 2014 Æ Accepted for
publication 11 April 2015
Hematol Oncol Stem Cell Ther 2015; 8(4): 181–184
ª 2015 King Faisal Specialist Hospital & Research Centre. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
DOI: http://dx.doi.org/10.1016/j.hemonc.2015.04.003The inv (4)(p13q13) cytogenetic abnormality is uncommon in hematologic malignancies. So far, it has not been
previously reported in patients with essential thrombocythemia (ET). We report a first case of ET with inv
(4)(p13q13) karyotype in a 69-year-old female patient who developed myelofibrosis at follow up.
Conventional cytogenetic analysis from a bone marrow sample showed 46, XX, inv (4)(p13q13) [3]/46, XX
[4] at diagnosis and subsequent analysis revealed the same abnormal karyotype during the myelofibrosis phase
(46, XX, inv (4)(p13q13) [13]/46, XX [26]). The prognostic significance of this chromosomal abnormality is
unknown.
KEYWORDS: Essential thrombocythemia; Myeloproliferative disorder; inv (4)(p13q13)Essential thrombocythemia (ET) is an acquiredmyeloproliferative disorder characterized byan increased number of platelets
(>450 · 109/L) in the circulating blood. ET shares
clinical, phenotypical and pathological similarities
with other myeloproliferative neoplasms (MPNs),
particularly polycythemia vera (PV) and primary
myeloﬁbrosis (PMF). ET is diagnosed by excluding
the presence of other MPNs, and by excluding causes
of reactive thrombocytosis. The incidence is approxi-
mately 1.5–2.5 per 100,000 population. The median
age at diagnosis is 65–70 years, but the disease may
occur at any age. The female to male ratio is approx-
imately 2:1.1–4 The most common complications are
vascular complications, including a tendency for
thrombosis, microvascular disturbances, and hemor-
rhage.5 Survival of ET patients does not substantially
differ from that of the general population. However,
the main causes of morbidity are vascular complica-
tions. Transformation to myelodysplastic syndrome
(MDS) or acute myeloid leukemia (AML) is anuncommon complication of ET, especially following
therapy with alkylating agents or radioactive
phosphorus.5,6
ET is a Philadelphia-negative classical myeloprolif-
erative neoplasm, having much in common with other
myeloproliferative neoplasms such as polycythemia
vera and primary myeloﬁbrosis.5 The Janus kinase 2
gene (JAK2) V617F mutation is detected in approx-
imately 50% of patients diagnosed with ET.7,8 The
incidence of clonal cytogenetic abnormalities in ET
is approximately 5%, but no speciﬁc abnormality has
been reported to date.9 We report a patient with
essential thrombocythemia, presenting with the
chromosomal abnormality: inv (4)(p13q13).CASES REPORT
In June 2012, a 69-year-old female patient was admit-
ted to the internal medicine outpatient clinic with a
complaint of excessive fatigue. Microcytic anemia
and thrombocytosis (Hb: 6.6 g/dl, MCV: 72 ﬂ,181
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WBC: 9.7 · 109/L, 1165 · 109/L) were detected in
complete blood count. Microcytic anemia was
consistent with iron deﬁciency anemia (IDA).
Gastrointestinal blood loss was investigated as a pos-
sible cause of IDA. Colonoscopy and biopsy were
consistent with the diagnosis of Crohn’s disease.
IDA was successfully treated. During this period sala-
zopyrine was started for Crohn’s disease. In retrospec-
tive analysis, thrombocytosis (approximately
1000 · 109/L) was determined to have been present
for about 5 years. Despite successful treatment of
IDA and Crohn’s disease, persistent thrombocytosis
was observed, and a chronic myeloproliferative neo-
plasm was subsequently investigated. No other causes
of reactive thrombocytosis were found. JAK-2 muta-
tion analysis and t(9; 22) were negative in the periph-
eral blood. Hypercellular bone marrow and
abundance of mature megakaryocytes and platelet
clumps were observed. No signiﬁcant increase in the
erythroid and myeloid series and no other malignant
inﬁltrations were observed. The patient’s karyotype
was determined with conventional cytogenetic analysis
in the bone marrow sample and was designated as 46,
XX, inv (4)(p13q13) [3]/46, XX [4] according to the
ISCN (International System for Human Cytogenetic
Nomenclature) 2013 (Fig. 1). Our patient was diag-
nosed with essential thrombocythemia according to
World Health Organization (WHO) 2008 criteria;
and because of high-risk ET, acetylsalicylic acid and
hydroxyurea therapy were initiated. The platelet
count decreased with this treatment but due to the
ensuing neutropenia it was discontinued and anagre-
lide (1 mg/day) was started. The patient was asymp-
tomatic and her complete blood count was normal,
except for mild anemia over a period of 1 year with
this treatment. After this period, severe anemia
occured and there were no causes to explain this ane-
mia. She became transfusion-dependent and a leuko-
erythroblastic blood ﬁlm was observed. At the same
time, splenomegaly was observed with abdominal
ultrasonography. A bone marrow biopsy was per-
formed and this revealed grade III reticular myeloﬁ-
brosis. The same cytogenetic abnormality was
detected (46, XX, inv (4)(p13q13) [13]/46, XX
[26]). She was diagnosed with post-essential throm-
bocythemia myeloﬁbrosis (post-ET MF). She remains
transfusion-dependent at follow up.DISCUSSION
ET is a chronic myeloproliferative neoplasm charac-
terized by a persistent elevated platelet count in the
peripheral blood and proliferation of enlargedmegakaryocytes in the bone marrow.10 Cytogenetic
abnormalities in ET patients are very rare at diagno-
sis. Approximately 5% of ET patients show cytoge-
netic abnormalities which are non-speciﬁc. The
most frequent cytogenetic abnormalities are trisomy
8, trisomy 9, and deletions of 13q and 20q.11,12 The
role of these chromosomal abnormalities as prognos-
tic indices in disease transformation is not sufﬁciently
studied.
In our case, persistent thrombocytosis was
observed and a chronic myeloproliferative neoplasm
was investigated. None of the cytogenetic abnormali-
ties mentioned above in ET patients were detected in
our patient. We observed a 46, XX, inv (4)(p13q13)
[3]/46, XX [4] karyotype in our case with conven-
tional cytogenetic analysis. This change is considered
a clonal cytogenetic abnormality in ET because it is
determined in 49% of metaphases.
To our knowledge, an inv (4)(p13q13) cytogenetic
abnormality has not been previously reported in
patients with ET. Although these pericentric inver-
sions of chromosome 4 have not been described in
other myeloproliferative disorders, they have been
observed in AML. The breakpoints determined in
our case are different from inversions of chromosome
4 previously described in cases with AML.13–16 On
the other hand, the same abnormality has been
reported in only one case who has recurrent preg-
nancy loss.17
The breakpoint involved in the short arm of chro-
mosome 4p13 in our case contains the RhoH/TTF
(ARHH) gene. The RhoH gene encodes a member
of the Ras superfamily of small GTPases and is
restrictively expressed in hematopoietic cells and tis-
sues.18 Its function in myeloid cells is unknown.
Activation of this gene with mechanism of inversion
may have an important role in the pathogenesis of
ET or hematological malignancy. The inv
(4)(p13q28) karyotype was previously reported in
two patients diagnosed with AML 13. One of the
breakpoints of the short arm of chromosome 4
(4p13) is the same as the breakpoint of our case.
This ﬁnding may be associated with a transformation
risk of ET patients to secondary myeloﬁbrosis. This
chromosomal abnormality was detected 2 years after
the diagnosis, at which time post-ET MF had devel-
oped. As far as we know, the other breakpoint of
inversion (4q13) does not contain any gene that has
been associated with ET or hematological malignan-
cies as yet.
This is the ﬁrst reported case of inv (4)(p13q13)
karyotype in ET. The prognostic signiﬁcance and
transformation to myeloﬁbrosis or AML, associatedHematol Oncol Stem Cell Ther 8(4) Fourth Quarter 2015
Fig. 1. Representative karyogram of bone marrow cells showing 46, XX, inv (4)(p13q13) karyotype.
INV (4)(P13Q13) CYTOGENETIC ABNORMALITY case reportwith this abnormality is not known. There are some
possible molecular mechanisms that could be associ-
ated with AML transformation. The RhoH gene,
which is associated with the breakpoint of chromo-
some 4p, might be responsible for this relation.
However, these possible mechanisms and our ﬁndings
need to be conﬁrmed and studied in further cases with
ET.
For all the reasons mentioned above, our patient
should be followed-up closely with cytogenetic analy-
sis and molecular cytogenetic analysis and molecularHematol Oncol Stem Cell Ther 8(4) Fourth Quarter 2015cytogenetic techniques for a possible higher risk of
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